Most Downloaded Articles
- A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens by Gilbert, Peter B./ Grove, Douglas/ Gabriel, Erin/ Huang, Ying/ Gray, Glenda/ Hammer, Scott M./ Buchbinder, Susan P./ Kublin, James/ Corey, Lawrence and Self, Steven G.
- Maximum a Posteriori Estimation in Dynamical Models of Primary HIV Infection by Drylewicz, Julia/ Commenges, Daniel and Thiebaut, Rodolphe
- Joint Spatio-Temporal Modeling of Mycobacterium bovis Infections in Badgers and Cattle – Results from the Irish Four Area Project by Kelly, Gabrielle E.
- Prediction of an Epidemic Curve: A Supervised Classification Approach by Nsoesie, Elaine O./ Beckman, Richard/ Marathe, Madhav and Lewis, Bryan
- Episodic HIV Risk Behavior Can Greatly Amplify HIV Prevalence and the Fraction of Transmissions from Acute HIV Infection by Zhang, Xinyu/ Zhong, Lin/ Romero-Severson, Ethan/ Alam, Shah Jamal/ Henry, Christopher J./ Volz, Erik M. and Koopman, James S.
Estimating Trends in Incidence, Time-to-Diagnosis and Undiagnosed Prevalence using a CD4-based Bayesian Back-calculation
1MRC Biostatistics Unit
2Health Protection Agency
3Health Protection Agency
4Health Protection Agency
5MRC Biostatistics Unit and Health Protection Agency
Citation Information: Statistical Communications in Infectious Diseases. Volume 4, Issue 1, ISSN (Online) 1948-4690, DOI: 10.1515/1948-4690.1055, November 2012
- Published Online:
There has been much recent speculation regarding the potential for HIV test-and-treat strategies to provide control of the HIV endemic. In the UK, despite advanced HIV surveillance and the implementation of a number of testing initiatives and attempts to widen access to antiretroviral drugs, the number of new diagnoses persists at a high level having risen considerably over the course of the last ten years. The extent to which this high level of diagnosis is attributable to levels of HIV transmission or improved rates of testing and diagnosis is unclear. To disentangle these competing factors, we use a Bayesian back-calculation based on HIV and AIDS diagnosis data augmented by observed CD4 count levels at diagnosis. The CD4 count acts as a prognostic marker indicative of the time-since-infection for any new diagnosis. In addition to estimating time-dependent rates of infection and diagnosis, we exploit the model structure to estimate posterior distributions for a number of key epidemiological quantities such as trends in the time-to-diagnosis and the time-since infection distributions as well as the prevalence of undiagnosed infection. These quantities are stratified by CD4 count where possible. The proposed methodology is applied to HIV/AIDS surveillance data from England & Wales uncovering a decreasing trend in the time to diagnosis and stable levels of incidence in recent years.